Cyclerion Therapeutics
CYCN
17 hedge funds and large institutions have $1.06M invested in Cyclerion Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.
13% more capital invested
Capital invested by funds: $932K → $1.06M (+$124K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.48% less ownership
Funds ownership: 13.78% → 11.3% (-2.5%)
6% less funds holding
Funds holding: 18 → 17 (-1)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.38K |
| 3 |
PW
Pandora Wealth
Oakbrook Terrace,
Illinois
|
+$33 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$15 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
-$28.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.78K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.04K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$597 |
| 5 |
EWP
Elevation Wealth Partners
Santa Rosa,
California
|
-$50 |
CYCN Hedge Fund Activity: Q2 2025 in Review
17 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2025, worth a combined $1.06M — up 13% from $932K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYCN and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.1K. The largest seller was Tyndall Capital Partners, cutting an estimated $28.6K.
- 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2025, down from 18 in Q1 2025.
- Funds reported $1.06M of Cyclerion Therapeutics stock for Q2 2025, up 13% quarter-over-quarter.
- 1 fund opened new Cyclerion Therapeutics positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Cyclerion Therapeutics buyer in Q2 2025 was Tower Research Capital (TRC), an estimated $5.1K added.
- The largest Cyclerion Therapeutics seller in Q2 2025 was Tyndall Capital Partners, an estimated $28.6K sold.
Based on aggregated 13F filings for Q2 2025.